price close busi februari
biomed devic servic
turn corner acceler growth leverag
horizon
upgrad ahead view compani approach
apex turnaround cusp multi-year cycl acceler
top-lin growth translat increment leverag opportun
beyond result noth chang view compani
report strong revenu growth across geographi especi impress
out-performance apac us knees/hip dental off-set somewhat
weak emea spine/cmf furthermor compani announc long-
await least perspect restructur plan believ underscor
belief strategic/operational/cultur turnaround taken root
compani comfort enough put long-term metric place maintain
view invest improv suppli chain new product cadenc
cultur chang account commercial-centr focu taken hold
compani final posit go offens rest
year suppli chain invest work inventori channel
annual invest sale market top-lin out-performance
begin lead addit leverag opportun improv investor sentiment
multipl expans continu drive stock higher share trade
today continu see valu given still trade discount
larg cap peer believ opportun time build posit buy
strateg cultur chang pay continu theme zimmer
repeatedli note high level energi excit within sale organ
improv suppli stabil led grow confid across sale team
world-wide highlight fda recent complet anoth inspect
warsaw north facil find observ otherwis posit
improv quality/manufactur manag express confid
issu solvabl latest remind bryan hanson ceo came
board late focus bulk attent resolv qualiti
suppli issu larg solv except warsaw acceler pace new
product launch improv sale forc morale/execut prioriti
larg accomplish prioriti follow result manag note
engin focu shift back toward innov prioriti give
increas confid technolog pipelin
pipelin updat reiter import pipelin product fuel
return sustain top/bottom line growth result show clear sign
dynam half overal knee growth relat rosa note still
rel control launch remind past year compani
significantli bolster product portfolio materi launch knee persona
partial persona cementless persona revis
extrem sidu stemless shoulder comprehens basepl system
well robot rosa knee product fill
materi gap portfolio view launch cementless knee particularli
import fill key competit gap vs come price premium
complementari rosa robot applic addit manag note
persona revis launch trend better anticip compani tripl
amount instrument set vs origin expect bottom line
set first time nearli four year commerci
channel equip least product standpoint go offens target
competit account well upsel exist custom premium technolog
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
restructur sign confid call manag outlin
restructur plan enabl lt margin expans also invest mid/long-
term growth opportun specif compani expect remov redund
cost center simplifi oper model re-alloc invest higher
growth opportun view bullish sign manag
comfort enough fundament turnaround set long-term goal
top-lin growth oper leverag restructur plan expect deliv
pre-tax save end support oper
margin cost charg next
come back om guidanc call om signal
annual realiz leverag end someth
expect prove conserv top-lin growth abl acceler
figur result vs estim consensu
guidanc call top-lin growth rang foreign
currenc impact expect neutral compar cg/consensu
pro forma ep expect guid rang
compar cg/consensu adjust oper margin guid
rang line estim compani
adjust tax rate expect line estim
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu prodwctactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
rel uncertainti surround on-going remedi suppli issu impact
revenu margin sum maintain pt base price-to-earnings
multipl appli pro-forma ep
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net zimmer biomet hold
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep ep chg share gener oper rate adjust growth ep ex growth ep ex
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
